Bipolar Disorder: Role of Immune-Inflammatory Cytokines, Oxidative and Nitrosative Stress and Tryptophan Catabolites

Current Psychiatry Reports

Volumn 17, Issue 2, 2015, Pages

  Anderson, George ^a   Maes, Michael ^b,c,d  

^a Eccleston Square   (United Kingdom)

^b DEAKIN UNIVERSITY   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Bipolar disorder; Depression; Inflammation; Mania; Melatonin; Oxidative and nitrosative stress; Tryptophan catabolites

Indexed keywords

CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; MELATONIN; N ACETYLSEROTONIN; NEUROLEPTIC AGENT; SEROTONIN; TRYPTOPHAN; REACTIVE NITROGEN SPECIES;

ADDICTION; BIPOLAR DISORDER; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CEREBELLUM; COGNITION; COMORBIDITY; DISEASE ASSOCIATION; HORMONE SYNTHESIS; HUMAN; LIFE EXPECTANCY; NITROSATIVE STRESS; OXIDATIVE STRESS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; IMMUNOLOGY; INFLAMMATION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY;

BIPOLAR DISORDER; CYTOKINES; HUMANS; INFLAMMATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; TRYPTOPHAN;

EID: 84921924119     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0541-1     Document Type: Review

References (102)

1. Merinkangas KR, Tohen M. Epidemiology of bipolar disorder in adults and children. In: Tsuang MT, Tohen MT, Jones PB, editors. Textbook in psychiatric epidemiology. Chichester: Wiley; 2011. p. 329–42.
2. Leussis MP, Madison JM, Petryshen TL. Ankyrin 3: genetic association with bipolar disorder and relevance to disease pathophysiology. Biol Mood Anxiety Disord. 2012;2(1):18.
3. Seifuddin F et al. Meta-analysis of genetic association studies on bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):508–18.
4. Frey BN et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47(4):321–32.
5. Maes M et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29(2):141–52.
6. Maes M et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995;34(4):301–9.
7. Maes M et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997;66(1):1–11.
8. Wadee AA et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175–9.
9. Anderson G et al. Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol Rep. 2013;65(6):1647–54.
10. Maes M et al. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets. 2014;18(5):495–512.
11. Moylan S et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev. 2014;45:46–62.
12. Berk M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–17.
13. Myint AM et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007;102(1–3):65–72.
14. Nievergelt CM et al. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(3):234–41.
15. Duffy A et al. Biological indicators of illness risk in offspring of bipolar parents: targeting the hypothalamic-pituitary-adrenal axis and immune system. Early Interv Psychiatry. 2012;6(2):128–37.
16. Berk M et al. Stage managing bipolar disorder. Bipolar Disord. 2014;16(5):471–7. This is a comprehensive analysis of recent conceptualizations of the neuroprogressive nature of bipolar disorder.
17. Gama CS et al. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr. 2013;35(1):70–4.
18. Rege S, Hodgkinson SJ. Immune dysregulation and autoimmunity in bipolar disorder: synthesis of the evidence and its clinical application. Aust N Z J Psychiatry. 2013;47(12):1136–51.
19. Westman J et al. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open. 2013;18:3(4).
20. Yee HA, Loh HS, Ng CG. The prevalence and correlates of alcohol use disorder amongst bipolar patients in a hospital setting, Malaysia. Int J Psychiatry Clin Pract. 2013;17(4):292–7.
21. Miller C, Bauer MS. Excess mortality in bipolar disorders. Curr Psychiatry Rep. 2014;16(11):499.
22. Markham JA, Koenig JI. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl). 2011;214:89–106.
23. Hamdani N et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148(2–3):444–8.
24. do Prado CH et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology. 2013;38(5):667–76. This is an interesting article showing significant changes in bipolar patients in regard to immune and intracellular signalling pathways.
25. Knijff EM et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord. 2006;8(6):740–50.
26. Drexhage RC et al. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun. 2011;25(6):1206–13.
27. Torres KC et al. Expression of neuronal calcium sensor-1 (NCS-1) is decreased in leukocytes of schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):229–34.
28. Abeer El-Sayed A, Ramy HA. Immunological changes in patients with mania: changes in cell mediated immunity in a sample from Egyptian patients. Egypt J Immunol. 2006;13(1):79–85.
29. Munkholm K et al. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47(9):1119–33. This is an important meta-analysis of cytokine changes in bipolar disorder patients.
30. Modabbernia A et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74(1):15–25. An important meta-analysis of cytokine changes across a range of studies involving bipolar disorder patients.
31. Barbosa IG et al. Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci. 2013;263:159–65.
32. Barbosa IG et al. Increased levels of adipokines in bipolar disorder. J Psychiatr Res. 2012;46:389–93.
33. Soeiro-de-Souza MG et al. Lithium decreases plasma adiponectin levels in bipolar depression. Neurosci Lett. 2014;564:111–4.
34. Dickerson F et al. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150(2):456–9.
35. Hsuchou H et al. C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem. 2012;30(5):1109–19.
36. Hope S et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res. 2013;145(1–3):36–42.
37. Remlinger-Molenda A et al. Activity of selected cytokines in bipolar patients during manic and depressive episodes. Psychiatr Pol. 2012;46(4):599–611.
38. Hsu JW et al. Association of thalamic serotonin transporter and interleukin-10 in bipolar I disorder: a SPECT study. Bipolar Disord. 2014;16(3):241–8.
39. Cetin T et al. Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry. 2012;12:158.
40. Brietzke E et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214–7.
41. Ortiz-Domínguez A et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596–602.
42. Becking K et al. The association between immune activation and manic symptoms in patients with a depressive disorder. Transl Psychiatry. 2013;3:e314.
43. Bai YM et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord. 2014;166:187–92.
44. Wieck A et al. Pro-inflammatory cytokines and soluble receptors in response to acute psychosocial stress: differential reactivity in bipolar disorder. Neurosci Lett. 2014;580:17–21.
45. Barbosa IG et al. A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status. J Affect Disord. 2014;157:41–4.
46. Knijff EM et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743–53.
47. Kim YK et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1–3):91–5.
48. Nassar A, Azab AN. Effects of lithium on inflammation. ACS Chem Neurosci. In press.
49. Goldstein BI et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Ch Adol Psychopharmacol. 2011;21:479–84.
50. Brambilla P et al. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry. 2014;4:e406. Important data on changes in monocyte and T cell-associated cytokines in bipolar disorder patients.
51. Muxel SM et al. NF-kB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-nacetyltransferase (AA-NAT) gene. PLoS ONE. 2012;7(12):e52010.
52. Barbosa IG et al. Altered intracellular signaling cascades in peripheral blood mononuclear cells from BD patients. J Psychiatr Res. 2013;47(12):1949–54.
53. Bartels M et al. Valproic acid treatment is associated with altered leukocyte subset development. J Clin Psychopharmacol. 2012;32(6):832–4.
54. Himmerich H et al. Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-Cd40-stimulated blood in vitro. Oxid Med Cell Longev. 2014;2014:806162.
55. Niles LP et al. Valproic acid up-regulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain. Int J Neuropsychopharmacol. 2012;15(9):1343–50.
56. Söderlund J et al. Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder. J Psychiatry Neurosci. 2011;36(2):114–8.
57. Shelton RC et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry. 2011;16(7):751–62.
58. Bahna SG et al. Regional upregulation of hippocampal melatonin MT2 receptors by valproic acid: therapeutic implications for Alzheimer’s disease. Neurosci Lett. 2014;576:84–7.
59. Anderson G, Maes M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets. 2014;13(5):817–27. An important summary of the potential roles of local melatonin across a host of conditions, including bipolar disorder.
60. Lotrich FE et al. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry. 2014;29(6):635–44.
61. Doganavsargil-Baysal O et al. Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol. 2013;28(2):160–7.
62. Volkert J, et al. Evidence for cognitive subgroups in bipolar disorder and the influence of subclinical depression and sleep disturbances. Eur Neuropsychopharmacol. In press.
63. Buoli M et al. The impact of mood episodes and duration of illness on cognition in bipolar disorder. Compr Psychiatry. 2014;55(7):1561–6.
64. Rosa AR et al. Clinical staging in bipolar disorder: focus on cognition and functioning. J Clin Psychiatry. 2014;75(5):e450–6.
65. Soczynska JK et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromol Med. 2011;13(2):93–116.
66. Mesman E, et al. Monocyte activation, brain-derived neurotrophic factor (BDNF), and S100B in bipolar offspring: a follow-up study from adolescence into adulthood. Bipolar Disord. In press.
67. Anderson G, Maes M. Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. Curr Pharm Des. 2014;20(23):3812–47. A comprehensive review on the biological changes, and their interconnectedness, occurring in depression.
68. Aydemir O, et al. Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr. In press.
69. Versace A et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry. 2014;19(2):200–8. Important data showing an association of oxidative stress with changes in central white matter.
70. Andreazza AC et al. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem. 2013;127(4):552–61.
71. Bortolasci CC et al. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord. 2014;159:23–30. Important data that contributes to the biological differentiation of unipolar and bipolar depression.
72. Banerjee U et al. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):56–61.
73. Khairova R et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep. 2012;5(3):680–2.
74. Tan DX et al. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes. J Pineal Res. 2013;54(2):127–38.
75. Wilson CB et al. Valproic acid effects in the hippocampus and prefrontal cortex in an animal model of post-traumatic stress disorder. Behav Brain Res. 2014;268:72–80.
76. Soeiro-de-Souza MG et al. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol. 2013;16(7):1505–12. An important article highlighting the changes occurring in neuroprogression in bipolar patients.
77. Abe N et al. Altered sirtuin deacetylase gene expression in patients with a mood disorder. J Psychiatr Res. 2011;45(8):1106–12.
78. Fernandes BS et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45(8):995–1004.
79. Iuvone PM et al. N-acetylserotonin: circadian activation of the BDNF receptor and neuroprotection in the retina and brain. Adv Exp Med Biol. 2014;801:765–71.
80. Anderson G, Maes M. Metabolic syndrome, Alzheimer’s, schizophrenia and depression: role for leptin, melatonin, kynurenine pathways and neuropeptides. Chap 13. In: Farooqui T, Farooqui AA, editors. Metabolic syndrome and neurological disorders. Chichester, UK: Wiley; 2013.
81. Johansson AS et al. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J Psychiatr Res. 2013;47(11):1815–23.
82. Lavebratt C et al. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry. 2014;19(3):334–41.
83. Reininghaus EZ et al. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2014;16(4):432–40. Preliminary data, but potentially of great importance, as the article highlights changes in tryptophan catabolites in bipolar patients.
84. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses. 2011;76:54–60.
85. Stubbs B, et al. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis. Acta Psychiatr Scand. In press.
86. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res. 2012;196(2–3):243–9.
87. Anderson G, Berk M, Maes M. Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand. 2014;129(2):83–97.
88. Hackel D et al. The connection of monocytes and reactive oxygen species in pain. PLoS One. 2013;8(5):e63564.
89. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol Lett. 2008;29(1):117–24. An article of considerable importance that highlights the role of the gut in driving inflammatory changes in mood disorders.
90. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. In press.
91. Elamin E et al. Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach. PLoS One. 2014;9(9):e107421.
92. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62(6):591–9.
93. Sommansson A et al. Melatonin inhibits alcohol-induced increases in duodenal mucosal permeability in rats in vivo. Am J Physiol Gastrointest Liver Physiol. 2013;305(1):G95–G105.
94. Bala S et al. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One. 2014;9(5):e96864.
95. Etain B et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet. 2012;21(18):4030–7.
96. Yu HN et al. Effects of fish oil with a high content of n-3 polyunsaturated fatty acids on mouse gut microbiota. Arch Med Res. 2014;45(3):195–20.
97. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27(2):113–9.
98. Robillard R et al. Sleep-wake cycle and melatonin rhythms in adolescents and young adults with mood disorders: comparison of unipolar and bipolar phenotypes. Eur Psychiatry. 2013;28(7):412–6.
99. Markus RP, Cecon E, Pires-Lapa MA. Immune-pineal axis: nuclear factor κB (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells. Int J Mol Sci. 2013;14(6):10979–97.
100. Romo-Nava F et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014;16(4):410–21. A very important article showing that melatonin can prevent the inflammatory and metabolic dysregulation associated with antipsychotic treatment of bipolar disorder.
101. Redlich R, et al. Brain morphometric biomarkers distinguishing unipolar and bipolar depression: a voxel-based morphometry-pattern classification approach. JAMA Psychiatry. 2014;71(11):1222–30.
102. Pinato L, et al. Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct Funct. In press.